Research output per year
Research output per year
Search results
-
2021
Response to: Correspondence on "g-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
Martinez Sanz, P., Van Rees, D. J., Matlung, H. L., Tytgat, G. A. M. & Franke, K., 1 Dec 2021, In: Journal for ImmunoTherapy of Cancer. 9, 12, e003983.Research output: Contribution to journal › Letter › peer-review
Open Access -
2017
RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131-I-metaiodobenzylguanidine. Huibregtse K et al. European Journal of Cancer 2016. 66:144–152
Ronckers, C. M., Tytgat, L., van den Heuvel-Eibrink, M. M., Teepen, J., Kremer, L. C. M., Clement, S. & van Santen, H. M., 1 May 2017, In: European Journal of Cancer. 77, p. 21-23 3 p.Research output: Contribution to journal › Letter › peer-review